News & Updates
Filter by Specialty:
Teclistamab demonstrates clinical activity for R/R MM
The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.
Teclistamab demonstrates clinical activity for R/R MM
11 Aug 2022
High vitamin B6 status tied to better survival in stage I–III colorectal cancer
Higher preoperative vitamin B6 status appears to improve the overall survival (OS) of patients with stage I‒III colorectal cancer (CRC), suggests a recent study.
High vitamin B6 status tied to better survival in stage I–III colorectal cancer
10 Aug 2022
Gastric disease prevalence peaks during middle age, late adulthood
There appears to be a twin-peak prevalence profile (TPP) for diseases of the stomach, including Helicobacter pylori (Hp) infection, gastric cancer (GC), gastric intraepithelial neoplasia (GIN), and gastritis, according to a recent China study. The first peak typically occurs during middle-adulthood while the second peak happens in late life.
Gastric disease prevalence peaks during middle age, late adulthood
10 Aug 2022
Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
08 Aug 2022
RATIONALE-208 subanalyses boost tislelizumab potential for HCC
The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.